Notch genes encode a family of highly conserved transmembrane receptors that have a general role in the regulation of differentiation in multicellular animals [1] . They function in a novel signaling pathway that variously can influence cell fate decisions, proliferation, and survival. The outcome of Notch signaling depends on the strength of the signaling stimulus and the context (or differentiation state) of the cells receiving it.
In addition to its physiologic roles, abnormal Notch signaling also contributes to cancer development. The first Notch receptor gene to be identified in humans, Notch1, was discovered through the analysis of DNA flanking the breakpoints of a recurrent t(7;9)(q34;q34.3) chromosomal translocation seen in a small subset (probably < 1%) of human pre-T-cell acute lymphoblastic neoplasms [2] . In subsequently developed animal models, the Notch1, Notch2, and Notch3 receptors all have been implicated in the transformation of immature T cells. This review will focus on the effects of pathophysiologic Notch signaling during T cell development and leukemogenesis. In doing so, we will compare and contrast various animal models of Notch-induced leukemias, discuss how these modeling studies have contributed to our understanding of the physiologic role of Notch in T cell development, and speculate on the nature of the signals that drive cellular transformation.
Notch receptor structure
Notch receptors are large transmembrane polypeptides comprised of multiple distinct structural domains. The extracellular portion of the receptor has a ligand-binding domain within a set of iterated epidermal growth factorlike repeats and a negative regulatory domain comprised of three LIN12/Notch repeats. The intracellular portions of all Notches include RAM domains, six iterated ankyrin-like repeats, and C-terminal PEST sequences.
Mammals have four Notch genes (Notch1, Notch2, Notch3, and Notch4) that show overlapping patterns of expression. The highest sequence homology among these receptors lies in the ankyrin repeat domain, whereas the greatest divergence occurs in residues lying between the ankyrin repeats and the C-terminal PEST sequences. In Notch1, this divergent region contains a proline-rich and glutamine-rich transcriptional activation domain (TAD) [3] . Immediately C-terminal of the ankyrin repeats of Notch1, Notch2, and Notch3, there is also an approximately 60-amino-acid sequence that includes a nuclear 
Notch signaling
Multiple lines of investigation have produced a consensus model for Notch signaling centered on a series of regulated proteolytic cleavages [5] (Fig. 1 
Notch1 and human T-cell acute lymphoblastic leukemia
In all t(7;9)-associated T-cell acute lymphoblastic leukemias (T-ALLs), the translocation juxtaposes the 3Ј end of Notch1 and T-cell receptor (TCR) ␤ promoter/enhancer sequences, which drive the expression of a series of abnormal truncated mRNAs encoding amino terminally deleted Notch1 polypeptides (Fig. 2) . The consequences are twofold: Notch1 expression is dysregulated and increased, and, by virtue of deletion of N-terminal sequences needed for membrane tethering, the t(7;9)-specific polypeptides show increased nuclear localization. These findings suggest that human Notch1associated T-ALLs stem from an exaggeration of one or more normal Notch1 functions.
Notch1 is highly expressed in developing thymocytes [2] and thus differs from other genes implicated in human T-ALL, such as TAL1, LMO1, and LMO2, which are not expressed in normal thymocytes and transform through dominant negative effects [24] . However, the expression 
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Binding of the extracellular domain of Notch receptors to ligands such as jagged1 causes two successive proteolytic cleavage events that require or are mediated by TACE and presenilins (PS), respectively. This allows nuclear translocation of the intercellular portion of notch (ICN). One major set of signals (1) generated by ICN require the downstream transcription factor CSL (for CBF1, Su[H], Lag-1), which is converted to a transcription activator on binding of ICN through the displacement of corepressors (CoR) and the recruitment of coactivators (CoA). The consequences of this interaction may be modified by other nuclear factors, such as mastermind (MAM) and SKIP (not shown), which form higher order complexes with ICN and CSL. ICN also participates in CSL-independent pathways (1) that may involve Deltex (Dx), a basic polypeptide found in the cytoplasm and nucleus, or currently unknown nuclear factors (X).
of Notch1 in thymocytes is dynamic, high in immature CD4-/CD8-(double negative) cells, low in more mature CD4+/CD8+ (double positive) cells, and intermediate in later stage CD4 and CD8 single positive cells [25] . The expression of Notch1 and its target, HES1, mirror one another [26••], implying that signaling also normally is downregulated in CD4+/CD8+ double positive thymocytes. Thus, transformation by the t(7;9) may involve persistent inappropriately strong Notch signaling in double positive thymocytes.
Experimental Notch1-induced leukemias
One productive approach has relied upon retroviral cotransduction of bone marrow derived hematolymphoid progenitors with transgenes encoding constitutively active forms of Notch1, such as ICN1, and markers such as green-fluorescent protein (GFP) [27,28,29••]. ICN1 transgenes drive the appearance of an abnormal population of double positive T cells in the bone marrow of normal or thymectomized recipient mice as early as day 21 after transplant. This effect complements observations that Notch1 deficiency blocks early thymicdependent and thymic-independent T cell development [30, 31] while leaving later stages of thymocyte development relatively unaffected [67] . Initially, the ICN1induced double positive population is composed of an oligoclonal population of small, noncycling cells that are GFP bright ICN1 hi , whereas ICN1 lo cells progress to both CD4+ and CD8+ single positive fates. By 6 weeks after transplant, highly aggressive disseminated T-ALLs develop that are uniformly GFP bright ICN1 hi , implying that they arise from the double positive population. Unlike the immature thymocytes found in the bone marrow 21 days after transplant, the leukemic cells consist of mono-clonal, cycling lymphoblasts. The apparent requirement for high doses of Notch1 signaling may be relevant to the induction or progression of human T-ALL, because the t(7;9) is reduplicated in the SUP-T1 T-ALL cell line derived from a sporadic human tumor [2].
To explore the role of context in transformation, RAG2 (recombination activating gene) -/-marrow cells were transduced with ICN1 transgenes [32] . Mice reconstituted with such cells have increased numbers of very early T cells relative to GFP control mice, but do not accumulate double positive cells or develop tumors. The T cell transforming activity of ICN1 is restored in a RAG2 -/-background by expression of a TCR␤ transgene, indicating a requirement for TCR␤/pre-T␣ receptormediated signals. Whether such signals merely allow T cell development to proceed to a stage (double positive) that is permissive for Notch1 transformation or play a more active collaborative role remains to be ascertained.
These studies suggest that Notch1 activity is sufficient to commit a common lymphoid progenitor to the T cell lineage and that Notch1 activity, in combination with pre-TCR signals, induces the development of thymusindependent double positive immature T cells. Why, then, do these cells arrest rather than undergoing further differentiation or negative selection? One plausible explanation is that the bone marrow is not conducive for further development. However, even in the thymus, high Notch1 activity blocks double positive cell differentiation [33•], which the authors suggest may involve the inhibition of mitogen activated protein (MAP) kinase. Of note, a MAP kinase phosphatase, lateral signalinduced phosphatase 1 (LIP1), is activated by Notch signaling in Caenorhabditis elegans [34], and analogous genes are attractive potential targets for Notch activity in developing T cells.
Thus, enforced Notch1 activity drives progenitors to the CD4+/CD8+ stage, but then inhibits further differentia tion ( Fig. 3 ). Why this pool of precocious Notch1-induced cells is at risk for transformation is unclear, because it is comprised mainly of resting cells resembling normal double positive thymocytes [32]. One possibility is that a rare premalignant clone harboring complementary mutations eventually reveals itself, a scenario supported by studies showing that Notch1 cooperates in the induction of T-ALL by E2A-PBX1 [35•] and c-MYC [36,37•] transgenes. Notch1 promotes the survival of several T-cell hybridomas when exposed to apoptotic stimuli [38, 39] , suggesting that antiapoptotic activities may contribute to transformation. However, this proposed function has not been confirmed clearly in vivo, and recent studies have suggested that Notch1 functions in thymocytes are distinct from and complementary to those of the antiapoptotic protein, bcl2 [40•]. Thus, although Notch signaling has been shown to prevent differentiation, induce proliferation [41, 42] , and block apoptosis in specific contexts, the specific mechanism by which Notch1 contributes to T cell transformation remains to be determined. the C-terminal TAD and PEST sequences. It is speculated that these insertions contribute to leukemogenesis by accentuating ligand-dependent activation of Cterminally truncated receptors, either by enhancing protein stability or removing sequences that interact with negative regulatory factors, such as Numb [68] . Work with other Notches has raised further issues pertaining to the role of C-terminal sequences. First, increased leukemogenicity in a strain of feline leukemia virus is associated with transduction of Notch2 sequences encoding only the RAM and ankyrin repeat domains [49] . The same group subsequently discovered an internal ribosomal entry sequence within genomic Notch2 sequences that can direct the translation of ICN2, suggesting a novel ligand-independent mechanism for production of biologically active forms of Notch [50] . Second, murine lines expressing an LCK-ICN3 transgene develop T-ALLs at high frequency [51••] . ICN3 has minimal transactivation activity and can even partially antagonize coexpressed ICN1 [52] , probably by competing for binding to CSL.
Notch1 is specifically oncotropic for T-cell progenitors
Several factors may explain these differences. The type and strength of Notch1 signals needed for transformation may be altered by pre-existent expression of other oncoproteins (for example, E2A-PBX1 or c-MYC). This is consistent with in vitro studies conducted with baby hamster kidney (BHK) cells, in which the TAD is not required for transformation in cooperativity with E1A [20,21]. It has also not been formally demonstrated that the structure/function relationships of membrane-bound and constitutively nuclear forms of N1 are identical, and it is conceivable that one or the other form may interact differentially with positive or negative modulators of Notch signaling. In the case of Notch2 and Notch3, discrepant results pertaining to the requirement for TAD activity may point to nonredundant signaling activities among Notch receptors. Although both Notch2 and Notch3 are normally expressed in developing thymocytes, their function during T cell development is less well understood than that of Notch1. A further complication stems from the ability of ICN1 to upregulate Notch3 expression [53] , suggesting that these two signaling pathways may interact during ICN1-mediated T cell transformation.
What are the leukemogenic Notch signals?
One potential mechanism is inhibition of E2A, a gene encoding two basic helix-loop-helix transcription factors, E12 and E47, that are important in lymphoid development [54] . E2A knockout mice have a very early block in B cell development and are prone to T-cell tumors [55] , a phenotype reminiscent of that produced by enforced Notch1 activity. Transgenic expression of Id1, an E2A inhibitory protein, leads to a similar phenotype [56] . Moreover, misexpression of TAL1, LMO1, or LMO2, the genes most commonly dysregulated in human T-ALL, also inhibits E2A activity [24].
In transient expression experiments, ICN1 inhibits E2Ainduced transcriptional activation [22,28], suggesting a common event linking various forms of human T-ALL. Precisely how ICN1 inhibits E2A is unknown. A previous study showed HES1, a CSL-dependent Notch target, also inhibits E2A activity, possibly through a competitive mechanism that prevents dimerization [57] . However, other data have pointed to a CSL-independent mechanism of inhibition [22] .
Rel-type transcription factors represent a second potential target for the leukemogenic effects of Notch, because certain members of this family, such as v-rel, induce T-ALL in animal models [58] . Thymocytes expressing the LCK-ICN3 transgene show strong activation of NF-B, and ICN3 can activate certain NF-Bsensitive reporter genes in transient expression assays [51••] . ICN1 has been shown to overcome CSLmediated repression of the NF-B2 promoter [59] , suggesting that it too may stimulate the activity of rel factors. However, invertebrate studies consistently have failed to detect genetic interaction between Notch-dependent and rel-dependent signaling, and data from other studies have suggested that ICN1 might have IB-like activity [60] .
A more general question is whether leukemogenic signals are mediated through CSL-dependent or independent pathways. CSL is the target of multiple Epstein-Barr virus proteins required for B cell transformation [61] [62] [63] , and likely is dysregulated in a number of human tumors. It has not been possible to produce ICN1-like phenotypes with constitutively active forms of CSL (Pear and Aster, Unpublished data, August 2000), and whether CSL activation is necessary for Notch-induced leukemias remains unknown.
Conclusions
Murine models have shown that Notch1, Notch2, and Notch3 are potent inducers of T-ALL, but only Notch1 is known to be mutated in human T-ALL, and then only in a small subset of tumors. However, small deletions or single amino acid substitutions in Notch have been shown to produce gain-of-function phenotypes in invertebrates [64] . Systematic high throughput sequencing of DNA from human tumors soon will determine the occurrence and frequency of subtle Notch abnormalities in human tumors, but still will leave open the issue of whether ligand-dependent signaling through normal receptors might contribute to the transformed phenotype. These questions are of potential therapeutic importance, because presenilin inhibitors developed recently [65] could be used to treat tumors in which Notch signaling is proteolysis-dependent, assuming that it is critical for tumor maintenance.
Other lingering questions involve the identity of the signals underlying Notch transformation, the basis for their remarkable T cell oncotropicity, the genetic events that collaborate with Notch to cause T-ALL in humans, and the specific mechanism by which Notch signaling contributes to transformation. The application of genomic approaches, such as gene expression profiling and single nucleotide polymorphism (SNP) analysis, should provide insight into these critical issues in the near future. [66] , this transgene contained the coding sequence for the entire TAD. Some founder lines showed an increase in CD8 lineage cells; however, other lines showed increases in both CD4 and CD8 single positive cells. Eventually, all Lck-ICN1 mice developed intrathymic T-cell tumors, consistent with the notion that Notch signaling must be precisely regulated. These results suggest that the role of Notch signaling in positive selection is likely to be more complex than simply directing CD8 development at the expense of CD4 development. This complexity also is evident from the work of Wolfer et al. [67] , who observed that knockout of Notch1 at the DN3 (CD25+CD44-) stage of thymocyte differentiation did not affect further T cell development, indicating that ICN1 is not essential beyond early stages of commitment to T cell fate. Wolfer et al. did not, however, rule out a role for Notch signaling by other family members in later T cell development. Deftos et al. also identified several transcripts, including HES1, pre-Ta, Meltrinb, deltex1, and Ifi-204, that are upregulated in response to Notch signaling in cell lines and whose expression mirrors that of Notch1 in developing T cells. It is not clear whether these transcripts are direct or indirect targets of Notch. The developmental block was dependent on the dose of ICN1 and was associated with impaired response to TCR stimulation. These results suggest that the decrease in Notch signaling from the double negative to double positive stage is requisite for further development, and that the failure to downregulate Notch signaling at this stage of development prevents further maturation. ICN1 also repressed transactivation of an AP1/NFAT reporter in Jurkat cells. The authors propose that Notch signaling modulates positive selection by titrating TCR signal strength, which is known to be potentiated by MAPK-dependent signals. One possible mechanism for an effect of ICN1 on MAPK has been identified by Berset et al. [34] , who showed that proper fate specification during C. elegans vulval development requires Notch-dependent upregulation of the MAPK phosphatase, LIP1. . TCR␣ knockout mice, in which MHC recognition and positive selection cannot occur, were used to study the signals that drive positive selection. Expression of either ICN1 lacking the C-terminal TAD or bcl-2 transgenes failed to rescue CD8 development, whereas expression of both restored CD8 but not CD4 development in the thymus. Although the CD8 single positive cells from the double transgenic mice secreted interleukin-2, they failed to either migrate to or survive in the periphery. In addition, thymocytes from bcl-2 transgenic mice, unlike those from ICN1 transgenic mice, showed prolonged survival in culture. The authors propose that ICN1 signaling rescues cell fate (CD8 development), whereas bcl-2 provides a survival signal. In contrast to these observations, forms of ICN1 containing the TAD have been shown by other investigators to inhibit steroid-induced [38] and TCRmediated [39] apoptosis of certain T-cell lines. Hence, ICN1 may have antiapoptotic properties in some contexts [38, 39] . 
